首页> 美国卫生研究院文献>Respiratory Research >Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

【2h】

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

机译：单独的Osimertinib作为脑转移的第二线治疗（BM）控制可能比Adaved NSCLC患者中的非BM患者更受限制获得预测的EGFR T790M突变

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Patients’ selection flowchart

机译：患者的选择流程图

著录项

期刊名称 Respiratory Research
作者
Changhui Li; Wei Nie; Jingdong Guo; Anning Xiong; Hua Zhong; Tianqing Chu; Runbo Zhong; Jianlin Xu; Jun Lu; Xiaoxuan Zheng; Bo Zhang; Yinchen Shen; Feng Pan; Baohui Han; Xueyan Zhang;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类呼吸生理学;
关键词
Osimertinib; Brain metastases; EGFR T790M mutation; Radiotherapy;

机译：Osimertinib;脑转移;EGFR T790M突变;放射疗法;

相似文献

外文文献
中文文献
专利

1. AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC [J] . Vassiliki A Papadimitrakopoulou Lung cancer management. . 2017,第4期

机译：AURA3试验：Tagrisso（osimertinib）是否有潜力成为EGFR T790M突变阳性局部晚期或转移性NSCLC患者二线治疗的新治疗标准
2. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib [J] . Hochmair Maximilian J., Buder Anna, Schwab Sophia, Targeted oncology . 2019,第1期

机译：基于液检查基于EGFR T790M突变介导的EGFR T790M突变介导的AFATINIB治疗患者患者的患者，以及随后对OSIMERTINIB的回应
3. P2.03-040 EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients [J] . C. Li, H. Liu, B. Zhang, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：P2.03-040 EGFR T790M突变检测和先进的NSCLC患者液体活检的Osimertinib治疗响应评估
4. Intratumor Heterogeneity of EGFR Activating Mutations in Advanced NSCLC Patients at Single-Cell Level [C] . Liu Yuefen International Conference on Biomedical Engineering, Machinery and Earth Science . 2018

机译：单细胞水平晚期NSCLC患者EGFR激活突变的细胞内异质性
5. AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC [O] . Vassiliki A Papadimitrakopoulou 2016

机译：AURA3试验：Tagrisso（osimertinib）是否有潜力成为EGFR T790M突变阳性局部晚期或转移性NSCLC患者二线治疗的新治疗标准
6. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation [O] . Changhui Li, Wei Nie, Jingdong Guo, 2021

机译：单独的Osimertinib作为脑转移的第二线治疗（BM）控制可能比Adaved NSCLC患者中的非BM患者更受限制，获得预测的EGFR T790M突变

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

摘要

著录项

相似文献

相关主题

期刊订阅